Literature DB >> 32822095

Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.

Jelte J Schaapman1, Maarten E Tushuizen2, Minneke J Coenraad2, Hildo J Lamb1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease in the world, affecting more than 25% of the adult population. NAFLD covers a spectrum including simple steatosis, in which lipid accumulation in hepatocytes is the predominant histological characteristic, and nonalcoholic steatohepatitis (NASH), which is characterized by additional hepatic inflammation with or without fibrosis. Liver biopsy is currently the reference standard to discriminate between hepatic steatosis and steatohepatitis. Since liver biopsy has several disadvantages, noninvasive diagnostic methods with high sensitivity and specificity are desirable for the analysis of NAFLD. Improvements in magnetic resonance imaging (MRI) technology are continuously being implemented in clinical practice, specifically multiparametric MRI methods such as proton density fat-fraction (PDFF), T2 *, and T1 mapping, along with MR elastography. Multiparametric imaging of the liver has a promising role in the clinical management of NAFLD with quantification of fat content, iron load, and fibrosis, which are features in NAFLD. In the present article, we review the utility and limitations of multiparametric quantitative imaging of the liver for diagnosis and management of patients with NAFLD. LEVEL OF EVIDENCE: 5. TECHNICAL EFFICACY STAGE: 3.
© 2020 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC. on behalf of International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  NAFLD; NASH; liver disease; magnetic resonance imaging; multiparametric; noninvasive

Mesh:

Year:  2020        PMID: 32822095     DOI: 10.1002/jmri.27292

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  Development and validation of a neural network for NAFLD diagnosis.

Authors:  Paolo Sorino; Angelo Campanella; Caterina Bonfiglio; Antonella Mirizzi; Isabella Franco; Antonella Bianco; Maria Gabriella Caruso; Giovanni Misciagna; Laura R Aballay; Claudia Buongiorno; Rosalba Liuzzi; Anna Maria Cisternino; Maria Notarnicola; Marisa Chiloiro; Francesca Fallucchi; Giovanni Pascoschi; Alberto Rubén Osella
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

2.  Multiparametric quantitative renal MRI in children and young adults: comparison between healthy individuals and patients with chronic kidney disease.

Authors:  Jonathan R Dillman; Stefanie W Benoit; Deep B Gandhi; Andrew T Trout; Jean A Tkach; Katherine VandenHeuvel; Prasad Devarajan
Journal:  Abdom Radiol (NY)       Date:  2022-03-02

3.  4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion.

Authors:  Arno A W Roest; Hildo J Lamb; Friso M Rijnberg; Jos J M Westenberg; Hans C van Assen; Joe F Juffermans; Lucia J M Kroft; Pieter J van den Boogaard; Covadonga Terol Espinosa de Los Monteros; Evangeline G Warmerdam; Tim Leiner; Heynric B Grotenhuis; Monique R M Jongbloed; Mark G Hazekamp
Journal:  J Cardiovasc Magn Reson       Date:  2022-03-28       Impact factor: 6.903

4.  Multiparametric MRI with MR elastography findings in patients with sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy.

Authors:  Ahmet Poker; Musturay Karcaaltıncaba; Mustafa N Ozmen; Ali D Karaosmanoğlu; Ahmet G Erdemir; Osman Ocal; Deniz Akata; Ilkay S Idilman
Journal:  Insights Imaging       Date:  2022-09-05

5.  Distribution and Associated Factors of Hepatic Iron-A Population-Based Imaging Study.

Authors:  Lisa Maier; Ricarda von Krüchten; Roberto Lorbeer; Jule Filler; Johanna Nattenmüller; Barbara Thorand; Wolfgang Koenig; Wolfgang Rathmann; Fabian Bamberg; Christopher L Schlett; Annette Peters; Susanne Rospleszcz
Journal:  Metabolites       Date:  2021-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.